Don't jump to rash conclusions

被引：5

作者：

Bebb, Gwyn ^{[1
,2
]}

Boland, William ^{[1
,2
]}

Melosky, Barbara ^{[3
,4
]}

机构：

[1] Tom Baker Canc Clin, Translat Res Lab, Calgary, AB, Canada

[2] Univ Calgary, Calgary, AB, Canada

[3] British Columbia Canc Agcy, Dept Med, Vancouver, BC V5Z 4E6, Canada

[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

来源：

CANCER BIOLOGY & THERAPY | 2011年 / 11卷 / 07期

关键词：

nimotuzumab; EGFR; EGFR inhibitors; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; PHASE-III TRIAL; MONOCLONAL-ANTIBODY; ERLOTINIB; NIMOTUZUMAB; CHEMOTHERAPY; CARCINOMA; CETUXIMAB; PLUS;

D O I：

10.4161/cbt.11.7.14920

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：639 / 641

页数：3

共 24 条

[1] Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status [J].

Akashi, Y. ;

Okamoto, I. ;

Iwasa, T. ;

Yoshida, T. ;

Suzuki, M. ;

Hatashita, E. ;

Yamada, Y. ;

Satoh, T. ;

Fukuoka, M. ;

Ono, K. ;

Nakagawa, K. .

BRITISH JOURNAL OF CANCER, 2008, 98 (04) :749-755

[2]

Arleaga ME, 2007, CANCER BIOL THER, V6, P1390

[3] Nimotuzumab with chemoradiation confers survival advantage in treatment naive head and neck tumors overexpressing EGFR [J].

Basavaraj, Chetana ;

Sierra, Patricia ;

Shivu, Jatteppanavar ;

Melarkode, Ramakrishnan ;

Montero, Enrique ;

Nair, Pradip .

CANCER BIOLOGY & THERAPY, 2010, 10 (07) :673-681

[4]

BEBB G, 2010, CANC CHEMOT IN PRESS

[5]

Bode U, 2007, J CLIN ONCOL, V25

[6] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].

Bonner, James A. ;

Harari, Paul M. ;

Giralt, Jordi ;

Cohen, Roger B. ;

Jones, Christopher U. ;

Sur, Ranjan K. ;

Raben, David ;

Baselga, Jose ;

Spencer, Sharon A. ;

Zhu, Junming ;

Youssoufian, Hagop ;

Rowinsky, Eric K. ;

Ang, K. Kian .

LANCET ONCOLOGY, 2010, 11 (01) :21-28

[7] A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results [J].

Choi, Hye Jin ;

Sohn, Joo Hyuk ;

Lee, Chang Geol ;

Shim, Hyo Sub ;

Lee, Ik-Jae ;

Yang, Woo Ick ;

Kwon, Ji Eun ;

Kim, Se Kyu ;

Park, Moo-Suk ;

Lee, Ju Hee ;

Kim, Joo Hang .

LUNG CANCER, 2011, 71 (01) :55-59

[8] Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer [J].

Crombet, T ;

Torres, L ;

Neninger, E ;

Catalá, M ;

Solano, ME ;

Perera, A ;

Torres, O ;

Iznaga, N ;

Torres, F ;

Pérez, R ;

Lage, A .

JOURNAL OF IMMUNOTHERAPY, 2003, 26 (02) :139-148

[9] Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial [J].

Gatzemeier, Ulrich ;

Pluzanska, Anna ;

Szczesna, Aleksandra ;

Kaukel, Eckhard ;

Roubec, Jaromir ;

De Rosa, Flavio ;

Milanowski, Janusz ;

Karnicka-Mlodkowski, Hanna ;

Pesek, Milos ;

Serwatowski, Piotr ;

Ramlau, Rodryg ;

Janaskova, Terezie ;

Vansteenkiste, Johan ;

Strausz, Janos ;

Manikhas, Georgy Moiseevich ;

Von Pawel, Joachim .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1545-1552

[10] Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study [J].

Gordon, AN ;

Finkler, N ;

Edwards, RP ;

Garcia, AA ;

Crozier, M ;

Irwin, DH ;

Barrett, E .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (05) :785-792

← 1 2 3 →